Camptothecin
Research stageAlso known as (S)-(+)-camptothecin, 20(S)-camptothecine, D-camptothecin, (+)-camptothecin+3 more
(S)-(+)-camptothecin, 20(S)-camptothecine, D-camptothecin, (+)-camptothecin, (+)-camptothecine, Camptothecine, 21,22-Secocamptothecin-21-oic acid lactone.
Recent clinical, regulatory, research and industry developments relating to this drug.
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology13
- The New England journal of medicine10
- Nature medicine5
- Clinical cancer research : an official journal of the American Association for Cancer Research3
- ESMO open3
- Annals of oncology : official journal of the European Society for Medical Oncology2
- Iwata H8
- Im SA7
- Kim SB7
- Hurvitz SA6
- Tsurutani J6
- Cortés J5
- Curigliano G5
- Park YH5
- Aichi Cancer Center Hospital8
- Dana-Farber Cancer Institute8
- Asan Medical Center6
- Memorial Sloan Kettering Cancer Center6
- National Cancer Center Hospital6
- National Cancer Center Hospital East6
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 15 of the same disease areas as Camptothecin in the shared literature.
Studied across 18 of the same disease areas as Camptothecin in the shared literature.
Studied across 10 of the same disease areas as Camptothecin in the shared literature.
Studied across 14 of the same disease areas as Camptothecin in the shared literature.
Studied across 10 of the same disease areas as Camptothecin in the shared literature.
Studied across 15 of the same disease areas as Camptothecin in the shared literature.
Studied across 15 of the same disease areas as Camptothecin in the shared literature.
Studied across 12 of the same disease areas as Camptothecin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature